Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb^®, GW572016) in an expanded panel of human normal and tumour cell lines

Abstract excerpt

OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines. Previous studies with a small number of cell lines suggest a correlation between overexpression of EGFR and/or HER2 and sensitivity to growth...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Fibroblast Growth Factor Research
• Share to HER2/EGFR in Cancer Research
• Share to Lung Cancer Treatments and Mutations